A consultative approach to service, delivery and problem solving ensured that a Polish pharmaceutical company received the equipment and technology it needed to ramp up production and expand into new geographies.
GEA has supplied one of the largest drug manufacturers in Korea with manufacturing equipment for a state-of-the-art pharma production plant. More than 7,000 VESTA® sterile valves were installed to direct the product flow in two identical insulin production lines. This was the first time VESTA® valve technology had been selected to completely equip a new greenfield project. The multimillion Euro order represents the biggest project so far in the history of the VESTA® line.
Caplin Group partners with GEA, a leading supplier of pharmaceutical containment equipment, to establish a state-of-the-art oncology plant in Chennai. Learn how Caplin's expansion plans and GEA's end-to-end solutions will enhance their production capabilities and deliver high-quality medicines.
Discover GEA's groundbreaking partnership with Oncogen Pharma in Malaysia, as they secure a multi-million Euro contract for the production of oral solid dosage (OSD) forms to treat cancer. Learn how GEA's end-to-end solutions and innovative technologies overcame challenges during the COVID-19 pandemic, ensuring successful project completion and customer satisfaction.
GEA’s first contained manufacturing line, including integrated granulation and tablet compression for the production of steroid/hormonal drugs, at STELLAPHARM in Vietnam is approaching completion
With the recent inclusion of a suite of fully automated, highly efficient production equipment to manufacture tablets and capsules, Pfizer’s plant in Freiburg, Germany, has been transformed into what the company calls a “Smart Factory.”
A partnership of pharmaceutical manufacturers and suppliers, including Pfizer, GEA and G-CON Manufacturing, welcomes GSK to a consortium dedicated to the development of a continuous technology solution for on-demand tablet production.
According to David Hobson, Sales Manager for Materials Handling Technology at GEA Pharma & Healthcare, it all started with a chance encounter at the ACHEMA 2012 trade show.
After conducting extensive market research, Penn Pharma identified an increased need in the solid dose oncology market for the outsourced development and production of highly toxic drugs. Its production site had been manufacturing potent solid dosage products for more than 20 years but needed additional capacity.
An Exergetic Life Cycle Assessment (ELCA) done at different levels can help to identify, localize and quantify the cumulative resource consumption patterns during the lifecycle of a product or service using a single indicator.
A team from Janssen Pharmaceutica initiated an in-depth feasibility study to assess the capabilities and constraints of ConsiGma®’s technology and process characteristics.
GEA and Cambridge Biostability Limited (CBL) have developed a revolutionary method of stabilizing vaccines using spray drying.
Project Sprint provided GEA with an opportunity to collaborate with key customer, supplier and academic groups as part of a strategy to develop a new generation of process intensification systems for drug product development and subsequent manufacturing.
The project team at a major pharmaceutical manufacturing company initiated an in-depth feasibility study to assess the capabilities and constraints of ConsiGma®’s technology and process characteristics.
To investigate continuous manufacturing (CM), and to streamline and accelerate its drug development process, Vertex Pharmaceuticals, Inc. partnered with GEA to enhance their existing technology and implement primary and backup CM processes.
When GEA supplied a complete oncology manufacturing line to a customer in India, they didn’t just ensure the health and safety of the operators — complying with internationally recognised standards — the company also increased yields, reduced production cycle times and implemented an ultimate containment solution.